CLINICAL TREATMENT Act

HR 6836, Clinical Treatment Act HR 3635, Local Coverage Determinations Act Prior Authorization S.2425-Patient Access and Medicare Protection Act (PAMPA) implementation. Support for legislation to freeze radiation therapy payments through the end of 2019, increase funding for the NIH for FY 2018 and FY 2019, and simplify the MIPS program; Balanced Budget Act of 2018 (HR 1892). Support for legislation to ensure patient safety and preserve the integrity of the Medicare program by ending abuses of the physician self-referral law for radiation therapy services; Protecting Integrity in Medicare Act (H.R. 2066) Support for structural changes that lead to delivering high-quality care for patients while increasing efficiencies and promoting Medicare sustainability; oppose radiation oncology benefit managers. Support for ensuring radiation oncologists participation in the Medicare electronic health record incentive program. Support for reforming the way Medicare pays for radiation oncology services by tying payments to quality and value. Implementation of H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 Support the elimination of abuse to the Medicare program by closing the in-office ancillary services exception to the Stark Law for radiation oncology services. S. 794 Local Coverage Determination Clarification Act of 2017

Client expense: $189,038 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Nuclear Regulatory Commission (NRC), Office of Management & Budget (OMB), SENATE

H.R. 6836, the CLINICAL TREATMENT Act H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)

Client expense: $79,366 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, all provisions H.R. 930, Lymphedema Treatment Act, all provisions S. 497, Lymphedema Treatment Act, all provisions H.R. 6836, CLINICAL TREATMENT Act, all provisions S. 3592, No More Surprise Medical Bills Act of 2018, all provisions H.R. 7122, Shared Accountability for Improved Patient Outcomes Act of 2018, all provisions H.R. 6, SUPPORT for Patients and Communities Act, all provisions S. 3120, HEAL Act of 2018, all provisions H.R.3528 - Every Prescription Conveyed Securely Act, all provisions S. 2460, Every Prescription Conveyed Securely Act, all provisions H.R. 2687, Medicaid Coverage for Addiction Recovery Expansion Act, all provisions S. 1169, Medicaid Coverage for Addiction Recovery Expansion Act, all provisions S. 1016, CONNECT for Health Act of 2017, provisions relating to telehealth Medicare program: Protecting Patients from Surprise Medical Bills Act Medicare program: Protecting Access to Medicare Act (PAMA)/physician office labs Medicare program: Medicare Access and Chip Reauthorization Act (MACRA) implementation Medicare program: Merit-based Incentive Payment System (MIPS) Medicare program: MIPS cost measures Medicare program: MIPS impact on Part B drugs and DME Medicare program: Physician-Focused Payment Model Technical Advisory Committee (PTAC) Medicare program: Diabetes Prevention Program/virtual coverage Medicare program: Evaluation and Management Codes/documentation Medicare program: Medicare physician fee schedule Medicare program: Medicare Advantage (MA) and Part D Medicare program: Quality Payment Program Medicare program: Shared Savings Program Medicare program: Health IT burdens Medicare program: Surprise billing Medicare program: Graduate Medical Education (GME) Medicare program: Alternative Payment Models (APMs) Medicare program: Appropriate Use Criteria Medicare program: Cybersecurity Medicare program: Interoperability Medicare program: Stark/Anti-kickback Medicare program: Privacy Medicare program: Regulatory relief Medicare program: Step therapy Medicare program: Residents/minor procedures Medicare program: Prior authorization and utilization management Medicare program: Medicare for all Medicare program: Open Payments Medicare program: PECOS/Medicare Enrollment/Revocations/Revalidations Medicare program: Pharmacy Benefit Manager (PBM)/drug price transparency Medicare program: Misvalued codes Medicare program: List price for drugs Medicare program: Drug pricing transparency

Client expense: $4,740,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Natl Drug Control Policy (NDCP), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office